BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter.

Medtronic data presented today reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.

Boston Scientific announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.

Patricia V. Blake will take over as CEO of the Heart Rhythm Society (HRS) next March, HRS leadership announced Oct. 26.

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

Is practice variation a real problem or a passing trend? Which metrics matter? Are there practical approaches healthcare leaders should use to tackle variation and, if so, how can they get their teams on board? Cardiologists and administrators weigh in.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.

Three decades after the first Transcatheter Cardiovascular Therapeutics conference, TCT.18’s organizers are moving “toward a more practical approach,” says Cardiovascular Research Foundation CEO Juan Granada, MD.